Treatment Overview
PGT-A (Preimplantation Genetic Testing for Aneuploidy) is an advanced embryo-screening procedure performed during IVF to evaluate all 23 pairs of chromosomes before transfer. The PGT-A Premium Program in Korea represents a comprehensive, technology-driven approach that integrates next-generation sequencing (NGS), AI-assisted embryo evaluation, and individualized treatment planning.
This premium program ensures embryos are chromosomally balanced and genetically healthy, significantly improving the success rate of implantation and live birth. Korean fertility centers have developed these programs to global excellence standards, offering patients precise genetic analysis, rapid turnaround, and patient-specific fertility management.
By combining cutting-edge genomics, micro-manipulation expertise, and ultra-secure cryopreservation systems, Korea’s PGT-A programs deliver some of the highest pregnancy success rates in Asia.
Purpose & Benefits
The main purpose of the PGT-A Premium Program is to identify chromosomally normal (euploid) embryos before transfer, preventing implantation failure and reducing the risk of miscarriage or genetic disorders.
Key Benefits:
- Higher pregnancy and live-birth rates: Only genetically normal embryos are selected for transfer.
- Reduced miscarriage risk: Detects chromosomal abnormalities (e.g., trisomy, monosomy) responsible for early pregnancy loss.
- Optimized embryo selection: Ensures that each embryo transferred has the highest implantation potential.
- Improved outcomes for older patients: Helps offset age-related chromosomal instability.
- Supports single embryo transfer (SET): Promotes safer pregnancies while maintaining high success rates.
- Emotional reassurance: Provides genetic assurance and reduces anxiety related to embryo quality.
- Efficient use of IVF cycles: Increases efficiency by avoiding transfers of chromosomally abnormal embryos.
Korea’s fertility programs combine science, technology, and compassionate care—ensuring a smooth, data-driven fertility journey for every patient.
Ideal Candidates
The PGT-A Premium Program is ideal for:
- Women aged 35 years and older, due to higher rates of aneuploidy in eggs.
- Couples with recurrent miscarriages or failed IVF attempts.
- Patients with previous chromosomal abnormalities in embryos or pregnancies.
- Couples seeking to avoid genetic syndromes such as Down, Edwards, or Turner syndrome.
- Carriers of chromosomal translocations or structural rearrangements.
- Patients using donor eggs or sperm, who want genetic validation before transfer.
- Cancer survivors or those undergoing fertility preservation before treatment.
The program is tailored through pre-treatment genetic evaluation, ovarian reserve testing, and a customized stimulation plan for each individual or couple.
Possible Risks & Complications
Although the PGT-A Premium Program is considered safe and reliable, some potential risks include:
- Embryo biopsy impact: A small risk of affecting embryo viability, minimized through advanced laser and micro-tools.
- Mosaicism: Mixed normal/abnormal cells within an embryo can lead to complex results.
- False positives/negatives: Extremely rare with NGS but may occur if biopsy sample is minimal.
- Ethical considerations: Decisions about discarding abnormal embryos can be emotionally challenging.
- Cost implications: Premium testing and advanced lab technology add to total IVF expense.
Korean fertility centers reduce these risks with strict quality controls, precision lab techniques, and experienced embryologists.
Techniques & Laboratory Methods
Korean fertility laboratories employ state-of-the-art technologies and methodologies for the PGT-A Premium Program:
1. Next-Generation Sequencing (NGS)
- Detects chromosomal gains, losses, and partial deletions with high sensitivity.
- Provides genome-wide coverage for all 23 pairs of chromosomes.
2. Trophectoderm Biopsy (Day 5–6 Blastocyst Stage)
- A few outer cells are carefully removed using laser micro-dissection, leaving the embryo intact.
- These cells accurately represent the embryo’s chromosomal composition.
3. Whole Genome Amplification (WGA)
- Amplifies DNA from a small number of cells to generate sufficient genetic material for testing.
4. AI-Assisted Embryo Selection
- Combines genetic data, embryo morphology, and developmental kinetics to rank embryos for transfer.
- Improves precision and reduces subjective variation in embryo selection.
5. Vitrification (Ultra-Rapid Freezing)
- Embryos are cryopreserved immediately after biopsy to maintain cellular integrity while awaiting genetic results.
6. Bioinformatics & Data Validation
- Korean clinics use advanced bioinformatic algorithms to ensure accuracy and consistency in results interpretation.
These advanced tools allow for faster, more accurate chromosomal screening with minimal embryo risk, forming the foundation of Korea’s premium genetic testing services.
Recovery & Aftercare
Because PGT-A occurs in the laboratory, physical recovery for the patient is minimal:
- Post-retrieval care: Rest for 24–48 hours after oocyte retrieval; mild cramping or bloating is normal.
- No downtime for testing: Embryos are cultured, biopsied, and frozen without affecting the patient’s schedule.
- Result review: Couples meet with genetic counselors and fertility specialists to discuss PGT-A results.
- Frozen embryo transfer (FET): Scheduled once genetically normal embryos are identified and the uterine environment is optimized.
- Emotional support: Ongoing counseling offered to manage anxiety, results interpretation, and future planning.
Korean fertility centers emphasize continuous care through every step—physical, emotional, and informational—ensuring a stress-free IVF experience.
Results & Longevity
Korea’s PGT-A Premium Programs demonstrate world-class outcomes supported by clinical data:
- Pregnancy rates: 65–75% per transfer of euploid embryos.
- Miscarriage reduction: Up to 70% lower than non-tested cycles.
- Live-birth rates: Over 60% with genetically normal embryos.
- Accuracy: > 99% reliability using NGS for chromosomal analysis.
- Safety: Negligible embryo damage rate (< 1%) using modern biopsy and vitrification techniques.
- Long-term outcomes: Healthy pregnancies and babies comparable to those from naturally conceived pregnancies.
Korean centers are globally recognized for their efficiency, precision, and compassionate clinical care.
Treatment Process in Korea
Step 1 – Consultation & Genetic Evaluation
- Comprehensive medical and genetic history review.
- Customized PGT-A plan based on patient’s age, reproductive goals, and medical background.
Step 2 – Ovarian Stimulation & Egg Retrieval
- Controlled ovarian stimulation with personalized medication dosing.
- Egg retrieval under mild sedation.
Step 3 – Fertilization & Embryo Culture
- ICSI (Intracytoplasmic Sperm Injection) often used to ensure successful fertilization.
- Embryos cultured to day 5–6 (blastocyst stage).
Step 4 – Trophectoderm Biopsy & Vitrification
- Embryologists extract 5–10 cells for testing using micro-lasers.
- Embryos frozen immediately for preservation.
Step 5 – Genetic Testing & Results Review
- NGS-based analysis identifies euploid embryos.
- Genetic counselors interpret results for patients.
Step 6 – Embryo Transfer
- Frozen embryo transfer of genetically normal embryos in a hormonally prepared cycle.
Why Korea Excels
- High-resolution sequencing technology and stringent laboratory standards.
- Integrated fertility-genomics collaboration between embryologists, molecular geneticists, and fertility physicians.
- AI-enhanced embryo selection for improved precision and reproducibility.
- Efficient workflow with fast turnaround of results (often within 7–10 days).
- Internationally accredited fertility centers offering bilingual care.
- Cost-effective access compared with similar programs in Western countries.
Korea’s focus on innovation and patient experience makes it a global hub for advanced fertility genetics.
Cost Range
The cost of the PGT-A Premium Program in Korea varies by clinic and number of embryos tested:
- PGT-A testing per batch (up to 5 embryos): USD 4,000 – 6,000
- Each additional embryo: USD 400 – 600
- IVF cycle + PGT-A package: USD 8,000 – 12,000
- Embryo biopsy and vitrification: USD 1,500 – 2,000
- Cryostorage (annual): USD 300 – 700
- Genetic counseling and follow-up: USD 300 – 500
Most clinics offer transparent package pricing that includes laboratory, testing, and storage services.
Popular Clinics in Korea
- CHA Fertility Center (Seoul / Bundang): Renowned for advanced PGT-A and integrated AI embryo selection.
- Maria Fertility Hospital: Offers premium genetic testing combined with innovative lab technology.
- MizMedi Women’s Hospital: Specializes in chromosomal testing, embryo biopsy, and long-term cryostorage.
- Hamchoon Women’s Clinic: Focused on personalized PGT protocols and molecular diagnostic services.
- Seoul National University Hospital Fertility Center: Academic-driven program integrating research and clinical excellence.
